Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Post Quarterly Sales of $13.06 Million

Share on StockTwits

Wall Street brokerages expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to post sales of $13.06 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $18.19 million and the lowest estimate coming in at $8.02 million. Lexicon Pharmaceuticals reported sales of $6.86 million during the same quarter last year, which indicates a positive year-over-year growth rate of 90.4%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year sales of $52.18 million for the current year, with estimates ranging from $35.25 million to $72.00 million. For the next year, analysts anticipate that the firm will post sales of $113.99 million, with estimates ranging from $63.46 million to $154.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.13). The company had revenue of $9.68 million during the quarter, compared to analysts’ expectations of $28.52 million. Lexicon Pharmaceuticals’s revenue was down 29.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.33) EPS.

A number of analysts recently weighed in on LXRX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, May 2nd. Stifel Nicolaus lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their target price for the company from $10.00 to $4.00 in a research note on Monday, July 29th. Citigroup decreased their target price on shares of Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, July 30th. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 19th. Finally, ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.63.

In related news, Director Sam L. Barker acquired 24,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Friday, August 2nd. The stock was acquired at an average price of $1.18 per share, with a total value of $28,320.00. Following the completion of the acquisition, the director now directly owns 40,187 shares of the company’s stock, valued at approximately $47,420.66. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its position in Lexicon Pharmaceuticals by 940.2% in the first quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 8,979 shares during the period. Wealth & Pension Services Group Inc. bought a new stake in shares of Lexicon Pharmaceuticals in the 1st quarter worth $60,000. Trexquant Investment LP bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth $92,000. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Lexicon Pharmaceuticals by 409.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 11,862 shares during the period. Finally, Quantitative Systematic Strategies LLC lifted its holdings in shares of Lexicon Pharmaceuticals by 67.2% in the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 8,302 shares during the period. Institutional investors and hedge funds own 97.95% of the company’s stock.

Shares of LXRX traded up $0.01 during midday trading on Wednesday, hitting $1.47. 696,417 shares of the stock traded hands, compared to its average volume of 974,878. Lexicon Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $11.88. The company has a market capitalization of $158.34 million, a price-to-earnings ratio of -1.29 and a beta of 0.77. The company’s 50 day simple moving average is $4.38.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.